JP MORGAN/CALL/VERTEX PHARMACEUTICALS/350/0.1/17.01.25 | Market Closed - Börse Stuttgart 03:05:13 26/06/2024 pm IST | ||
| 13.08 EUR | -1.13% |
|
| Current month | +23.28% | ||
| 1 month | +15.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 13.08 | -1.13% |
| 25/24/25 | 13.23 | +3.52% |
| 24/24/24 | 12.78 | -2.14% |
| 21/24/21 | 13.06 | +5.07% |
| 20/24/20 | 12.43 | -0.72% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 03:05 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL09PZ |
| ISIN | DE000JL09PZ9 |
| Date issued | 12/04/2023 |
| Strike | 350 $ |
| Maturity | 17/01/2025 (205 Days) |
| Parity | 10 : 1 |
| Emission price | 5.07 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14 € |
|---|---|
| Lowest since issue | 5.31 € |
| Spread | 0.01 € |
| Spread % | 0.08% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Warrants
- Warrant
